Actively Recruiting
Phase 1 Study of Single-Dose Zanzalintinib to Assess Safety and Drug Levels in Adults with Moderate Liver Impairment Compared to Healthy Adults
Led by Exelixis · Updated on 2025-06-22
20
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the drug zanzalintinib behaves in the body of adults with moderate liver impairment compared to healthy adults with normal liver function. The study focuses on measuring how the drug is absorbed, distributed, and cleared in participants, aiming to understand its pharmacokinetics and safety. This is a Phase 1, open-label trial sponsored by Exelixis. Participants are divided into two groups those with moderate hepatic impairment and matched healthy controls. Both groups will receive a single oral dose of zanzalintinib on Day 1. The participants with liver impairment must meet specific clinical criteria including stable liver function and classification by the Child-Pugh system. Healthy controls are matched by age, sex, and smoking status to the impaired group. During the study, researchers will collect blood samples before dosing and up to seven days after to measure drug levels and timing of peak concentration. Safety will be monitored for up to 30 days after dosing. Participants must avoid blood donation during and after the study. The total time involved for participants includes the dosing day and follow-up visits as scheduled, with careful monitoring of drug effects and any adverse events.
CONDITIONS
Brief Title
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Research Team
E
Exelixis Clinical Trials
B
Backup or International
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here